994220903	994220903	CD	B-NP	O
|	|	NN	I-NP	O
YMC	YMC	NN	I-NP	O
|	|	NN	I-NP	O
47066262	47066262	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
2443784	2443784	CD	B-NP	O
|	|	CC	I-NP	O
6/12/2006	6/12/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
PERIPHERAL	PERIPHERAL	NNP	I-NP	O
ARTERY	ARTERY	NNP	I-NP	O
DISEASE	DISEASE	NNP	I-NP	O
,	,	,	O	O
CONGESTIVE	CONGESTIVE	NNP	B-NP	O
HEART	HEART	NNP	I-NP	O
FAILURE	FAILURE	NNP	I-NP	O
,	,	,	O	O
CHRONIC	CHRONIC	NNP	B-NP	O
RENAL	RENAL	NNP	I-NP	O
FAILURE	FAILURE	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/7/2006	5/7/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/1/2006	10/1/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
MULLALY	MULLALY	NN	B-NP	O
,	,	,	O	O
DOMINIQUE	DOMINIQUE	NNP	B-NP	O
THEO	THEO	NNP	I-NP	O
MD	MD	NNP	I-NP	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
interim	interim	JJ	I-NP	O
dictation	dictation	NN	I-NP	O
from	from	IN	B-PP	O
7/3/06	7/3/06	CD	B-NP	O
through	through	IN	B-PP	O
04	04	CD	B-NP	O
while	while	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
General	General	NNP	I-NP	O
Medicine	Medicine	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
SYSTEM	SYSTEM	NN	I-NP	O
:	:	:	O	O
Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
likely	likely	RB	B-ADJP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
postoperative	postoperative	JJ	I-NP	O
course	course	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
contrast	contrast	NN	B-NP	O
induced	induce	VBD	B-VP	O
oliguric	oliguric	JJ	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
renal	renal	JJ	I-NP	O
consult	consult	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
on	on	IN	B-PP	O
2/6/06	2/6/06	CD	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Studdard	Studdard	NNP	I-NP	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
her	her	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
on	on	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Cowlin	Cowlin	NNP	I-NP	O
that	that	WDT	B-NP	O
her	her	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
due	due	JJ	B-ADVP	O
to	to	TO	B-PP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
from	from	IN	B-PP	O
renovascular	renovascular	JJ	B-NP	O
disease	disease	NN	I-NP	O
or	or	CC	O	O
possibly	possibly	RB	B-ADJP	O
due	due	JJ	I-ADJP	O
to	to	TO	B-PP	O
interstitial	interstitial	JJ	B-NP	O
nephritis	nephritis	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
drug	drug	NN	I-NP	O
allergy	allergy	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Shope	Shope	NNP	I-NP	O
,	,	,	O	O
Erik	Erik	NNP	B-NP	O
Garret	Garret	NNP	I-NP	O
Manuel	Manuel	NNP	I-NP	O
F.	F.	NNP	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
Nephrology	Nephrology	NNP	I-NP	O
Department	Department	NNP	I-NP	O
while	while	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
an	an	DT	B-NP	O
inpatient	inpatient	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
consideration	consideration	NN	B-NP	O
of	of	IN	B-PP	O
possibilities	possibility	NNS	B-NP	O
causing	cause	VBG	B-VP	O
her	her	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
her	her	PRP	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
was	be	VBD	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
cholesterol	cholesterol	NN	B-NP	O
emboli	emboli	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
eosinophilia	eosinophilia	NN	I-NP	O
,	,	,	O	O
stepwise	stepwise	JJ	B-NP	O
progression	progression	NN	I-NP	O
of	of	IN	B-PP	O
renal	renal	JJ	B-NP	O
impairment	impairment	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
a	a	DT	B-NP	O
nephrologist	nephrologist	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
known	know	VBN	I-VP	O
renal	renal	JJ	B-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
that	that	WDT	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
contributed	contribute	VBN	I-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
possible	possible	JJ	I-NP	O
drug	drug	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
diuril	diuril	VB	I-VP	O
and	and	CC	O	O
perhaps	perhaps	RB	B-ADVP	O
a	a	DT	B-NP	O
component	component	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
acute	acute	JJ	B-NP	O
interstitial	interstitial	JJ	I-NP	O
nephritis	nephritis	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
1/27/06	1/27/06	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
gross	gross	JJ	B-NP	O
hematuria	hematuria	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
urinalysis	urinalysis	NN	I-NP	O
showed	show	VBD	B-VP	O
red	red	JJ	B-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
but	but	CC	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
for	for	IN	B-PP	O
ATN	ATN	NN	B-NP	B-protein
.	.	.	O	O

This	This	DT	B-NP	O
gross	gross	JJ	I-NP	O
hematuria	hematuria	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
worsened	worsen	VBN	I-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
renal	renal	JJ	I-NP	O
ultrasound	ultrasound	NN	I-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
obstruction	obstruction	NN	I-NP	O
.	.	.	O	O

Gradually	Gradually	RB	B-ADVP	O
with	with	IN	B-PP	O
resolution	resolution	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
urine	urine	NN	I-NP	O
output	output	NN	I-NP	O
increased	increase	VBD	B-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
improved	improve	VBD	B-VP	O
with	with	IN	B-PP	O
supportive	supportive	JJ	B-NP	O
measures	measure	NNS	I-NP	O
alone	alone	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
gradual	gradual	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
urine	urine	NN	I-NP	O
output	output	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
decreased	decrease	VBD	B-VP	O
to	to	TO	B-PP	O
2.8	2.8	CD	B-NP	O
prior	prior	JJ	I-NP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
off	off	RP	B-PRT	O
diuretics	diuretic	NNS	B-NP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Daily	Daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
and	and	CC	O	O
if	if	IN	B-SBAR	O
her	her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
increases	increase	VBZ	B-VP	O
by	by	IN	B-PP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
3	3	CD	I-NP	O
pounds	pound	NNS	I-NP	O
Dr.	Dr.	NNP	B-NP	O
Bockoven	Bockoven	NNP	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
notified	notify	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
calcitriol	calcitriol	NN	B-NP	O
given	give	VBN	B-VP	O
elevation	elevation	NN	B-NP	O
of	of	IN	B-PP	O
parathyroid	parathyroid	NN	B-NP	O
hormone	hormone	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
Rate	Rate	NN	B-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
slow	slow	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
metoprolol	metoprolol	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
6	6	CD	I-NP	O
h.	h.	NN	I-NP	O
for	for	IN	B-PP	O
rate	rate	NN	B-NP	O
control	control	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
this	this	DT	B-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
to	to	TO	B-PP	O
12.5	12.5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-NP	O
twice	twice	RB	I-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
some	some	DT	B-NP	O
bradycardia	bradycardia	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
telemetry	telemetry	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Flecainide	Flecainide	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
12	12	CD	I-NP	O
h	h	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
these	these	DT	B-NP	O
two	two	CD	I-NP	O
medications	medication	NNS	I-NP	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
for	for	IN	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
pulmonary	pulmonary	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
become	become	VB	I-VP	O
volume	volume	NN	B-NP	O
overloaded	overload	VBN	B-VP	O
on	on	IN	B-PP	O
physical	physical	JJ	B-NP	O
examination	examination	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
,	,	,	O	O
elevation	elevation	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
JVP	JVP	NN	I-NP	B-protein
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
postoperative	postoperative	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
medical	medical	JJ	I-NP	O
Service	Service	NN	I-NP	O
on	on	IN	B-PP	O
2/10/06	2/10/06	CD	B-NP	O
for	for	IN	B-PP	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
undergo	undergo	VB	I-VP	O
a	a	DT	B-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
renally	renally	RB	B-NP	O
dosed	dose	VBN	I-NP	O
dopamine	dopamine	NN	I-NP	O
to	to	TO	B-VP	O
see	see	VB	I-VP	O
if	if	IN	B-SBAR	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
improved	improve	VBD	B-VP	O
her	her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
output	output	NN	I-NP	O
and	and	CC	O	O
renal	renal	JJ	B-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
improvement	improvement	NN	I-NP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
and	and	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
short	short	JJ	I-NP	O
trial	trial	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
diuresis	diuresis	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
as	as	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
acute	acute	JJ	B-NP	O
worsening	worsening	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
renal	renal	JJ	I-NP	O
function	function	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
been	be	VBN	I-VP	O
related	relate	VBN	I-VP	O
to	to	TO	B-PP	O
over	over	IN	B-PP	O
aggressive	aggressive	JJ	B-NP	O
diuresis	diuresis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
instead	instead	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
spironolactone	spironolactone	NN	B-NP	O
for	for	IN	B-PP	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
stated	state	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
daily	daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
checked	check	VBD	B-VP	O
.	.	.	O	O

Ischemia	Ischemia	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
statin	statin	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

Hematology	Hematology	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
supplementation	supplementation	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
anemia	anemia	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
briefly	briefly	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
on	on	IN	B-PP	O
1/27/06	1/27/06	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
evaluated	evaluate	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Hematology	Hematology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Codilla	Codilla	NNP	I-NP	O
and	and	CC	O	O
Dr.	Dr.	NNP	B-NP	O
Vallas	Vallas	NNP	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
Hematology	Hematology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
for	for	IN	B-PP	O
workup	workup	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
elevation	elevation	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
to	to	TO	B-PP	O
5.8	5.8	CD	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
slight	slight	JJ	I-NP	O
reduction	reduction	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
to	to	TO	B-PP	O
25	25	CD	B-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
elevation	elevation	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
PTT	PTT	NN	I-NP	O
to	to	TO	B-PP	O
97	97	CD	B-NP	O
.	.	.	O	O

Workup	Workup	NN	B-NP	B-protein
included	include	VBD	B-VP	I-protein
factor	factor	NN	B-NP	I-protein
7	7	CD	I-NP	I-protein
level	level	NN	I-NP	O
,	,	,	O	O
mixing	mix	VBG	B-VP	O
study	study	NN	B-NP	O
,	,	,	O	O
anticardiolipin	anticardiolipin	NN	B-NP	B-protein
antibody	antibody	NN	I-NP	I-protein
,	,	,	O	O
lupus	lupus	NN	B-NP	O
anticoagulant	anticoagulant	NN	I-NP	O
,	,	,	O	O
Von	Von	NNP	B-NP	O
Willebrand	Willebrand	NNP	I-NP	O
's	's	POS	B-NP	O
panel	panel	NN	I-NP	O
,	,	,	O	O
hepatitis	hepatitis	NN	B-NP	O
B	B	NN	I-NP	O
and	and	CC	I-NP	O
C	C	NN	I-NP	O
testing	testing	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
complement	complement	NN	B-NP	O
levels	level	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
packed	packed	JJ	B-NP	B-cell_type
red	red	JJ	I-NP	I-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
of	of	IN	B-PP	O
FFP	FFP	NN	B-NP	B-protein
on	on	IN	B-PP	O
1/27/06	1/27/06	CD	B-NP	O
as	as	RB	I-NP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
vitamin	vitamin	NN	B-NP	O
K	K	NN	I-NP	O
with	with	IN	B-PP	O
much	much	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
and	and	CC	I-NP	O
increase	increase	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
to	to	TO	B-PP	O
about	about	IN	B-NP	O
29	29	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
not	not	RB	I-VP	O
receive	receive	VB	I-VP	O
any	any	DT	B-NP	O
heparin	heparin	NN	I-NP	O
flushes	flush	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
for	for	IN	B-PP	O
DIC	DIC	NN	B-NP	O
or	or	CC	I-NP	O
hemolysis	hemolysis	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
was	be	VBD	B-VP	O
most	most	RBS	I-VP	O
likely	likely	RB	I-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
residual	residual	JJ	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
with	with	IN	B-PP	O
factor	factor	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
decreased	decrease	VBN	I-NP	O
renal	renal	JJ	I-NP	O
clearance	clearance	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
results	result	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
screen	screen	NN	I-NP	O
are	be	VBP	B-VP	O
pending	pende	VBG	B-ADJP	O
and	and	CC	O	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
up	up	RP	B-PRT	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
INR	INR	NN	I-NP	O
goal	goal	NN	I-NP	O
is	be	VBZ	B-VP	O
2	2	CD	B-NP	O
to	to	TO	I-NP	O
3	3	CD	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dosing	dosing	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Hynum	Hynum	NNP	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
current	current	JJ	I-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
is	be	VBZ	B-VP	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
INR	INR	NN	I-NP	O
1.2	1.2	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Hematology	Hematology	NN	B-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
wound	wound	JJ	I-NP	O
culture	culture	NN	I-NP	O
that	that	WDT	B-NP	O
grew	grow	VBD	B-VP	O
pseudomonas	pseudomona	NNS	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
briefly	briefly	NN	B-NP	O
treated	treat	VBN	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ceftazidime	ceftazidime	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
completed	complete	VBD	B-VP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ceftazidime	ceftazidime	NN	B-NP	O
and	and	CC	O	O
remained	remain	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
off	off	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
active	active	JJ	B-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
wound	wound	JJ	I-NP	O
care	care	NN	I-NP	O
consult	consult	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
decubitus	decubitus	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
DuoDERM	DuoDERM	NNP	B-NP	O
dressing	dress	VBG	B-VP	O
applied	apply	VBN	I-VP	O
every	every	DT	B-NP	O
three	three	CD	I-NP	O
days	day	NNS	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
despite	despite	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
show	show	VB	I-VP	O
clinical	clinical	JJ	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
is	be	VBZ	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
atelectasis	atelectasis	NN	B-NP	O
,	,	,	O	O
deconditioning	deconditioning	NN	B-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
her	her	PRP	B-NP	O
known	known	JJ	I-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
likely	likely	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
requires	require	VBZ	B-VP	O
supplemental	supplemental	JJ	B-NP	O
oxygen	oxygen	NN	I-NP	O
at	at	IN	B-PP	O
2	2	CD	B-NP	O
liters	liter	NNS	I-NP	O
nasal	nasal	JJ	B-NP	O
cannula	cannula	NN	I-NP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
oxygen	oxygen	NN	B-NP	O
saturations	saturation	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
90s	90	NNS	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
at	at	IN	B-PP	O
her	her	PRP$	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Diabetes	Diabetes	NNP	I-NP	O
Nursing	Nursing	NNP	I-NP	O
Service	Service	NNP	I-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
Avandia	Avandia	NNP	B-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
Lantus	Lantus	NNP	B-NP	O
and	and	CC	I-NP	O
NovoLog	NovoLog	NNP	I-NP	O
before	before	IN	B-PP	O
meals	meal	NNS	B-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
Avandia	Avandia	NNP	B-NP	O
4	4	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
every	every	DT	B-NP	O
noon	noon	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
NovoLog	NovoLog	NNP	B-NP	O
4	4	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-ADJP	O
before	before	IN	B-PP	O
every	every	DT	B-NP	O
meals	meal	NNS	I-NP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
NovoLog	NovoLog	NNP	I-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
thyroid	thyroid	NN	B-NP	O
supplementation	supplementation	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
Synthroid	Synthroid	NNP	B-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Fluids	Fluid	NNS	B-NP	O
,	,	,	I-NP	O
electrolytes	electrolyte	NNS	I-NP	O
and	and	CC	I-NP	O
nutrition	nutrition	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
hyponatremia	hyponatremia	NN	B-NP	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
and	and	CC	O	O
total	total	JJ	B-NP	O
body	body	NN	I-NP	O
water	water	NN	I-NP	O
excess	excess	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
improved	improve	VBD	B-VP	O
somewhat	somewhat	RB	B-ADVP	O
with	with	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
dysphagia	dysphagia	NN	B-NP	O
with	with	IN	B-PP	O
liquids	liquid	NNS	B-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
evaluated	evaluate	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Speech	Speech	NNP	I-NP	O
and	and	CC	I-NP	O
Swallow	Swallow	NNP	I-NP	O
Service	Service	NNP	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
aspiration	aspiration	NN	B-NP	O
on	on	IN	B-PP	O
bedside	bedside	NN	B-NP	O
swallow	swallow	NN	I-NP	O
examination	examination	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
video	video	NN	B-NP	O
swallow	swallow	NN	I-NP	O
examination	examination	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
evaluated	evaluate	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
ENT	ENT	NNP	I-NP	O
Service	Service	NNP	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Cassetty	Cassetty	NNP	I-NP	O
on	on	IN	B-PP	O
11/26/06	11/26/06	CD	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
laryngoscopy	laryngoscopy	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
vocal	vocal	JJ	I-NP	O
cord	cord	NN	I-NP	O
paralysis	paralysis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
MRI	MRI	NN	B-NP	O
imaging	imaging	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
neck	neck	NN	I-NP	O
and	and	CC	I-NP	O
chest	chest	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
mediastinal	mediastinal	JJ	B-NP	O
mass	mass	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
abnormalities	abnormality	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
recurrent	recurrent	JJ	I-NP	O
laryngeal	laryngeal	JJ	I-NP	O
nerve	nerve	NN	I-NP	O
were	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
.	.	.	O	O

Gradually	Gradually	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
hoarseness	hoarseness	NN	I-NP	O
and	and	CC	I-NP	O
dysphagia	dysphagia	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
benefits	benefit	VBZ	B-VP	O
from	from	IN	B-PP	O
turning	turn	VBG	B-VP	O
her	her	PRP$	B-NP	O
head	head	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
left	leave	VBN	I-NP	O
with	with	IN	B-PP	O
each	each	DT	B-NP	O
swallow	swallow	NN	I-NP	O
to	to	TO	B-VP	O
minimize	minimize	VB	I-VP	O
the	the	DT	B-NP	O
risk	risk	NN	I-NP	O
of	of	IN	B-PP	O
aspiration	aspiration	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Nutrition	Nutrition	NNP	I-NP	O
Service	Service	NNP	I-NP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

Vascular	Vascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
left	leave	VBD	B-VP	O
femoral	femoral	JJ	B-NP	O
distal	distal	JJ	I-NP	O
bypass	bypass	NN	I-NP	O
on	on	IN	B-PP	O
8/21/06	8/21/06	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
three	three	CD	B-NP	O
t.i.d.	t.i.d.	JJ	I-NP	O
wet-to-dry	wet-to-dry	JJ	I-NP	O
dressings	dressing	NNS	I-NP	O
applied	apply	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
up	up	RB	B-ADVP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
thigh	thigh	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
in	in	IN	B-PP	O
Vascular	Vascular	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Skreen	Skreen	NNP	I-NP	O
in	in	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Allergy	Allergy	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
DIURIL	DIURIL	NN	I-NP	O
induced	induce	VBN	I-NP	O
drug	drug	NN	I-NP	O
rash	rash	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
mucous	mucous	JJ	B-NP	O
membrane	membrane	NN	I-NP	O
involvement	involvement	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
Stevens-Johnson	Stevens-Johnson	JJ	B-NP	O
syndrome	syndrome	NN	I-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
PPI	PPI	NN	I-NP	B-protein
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
her	her	PRP$	B-NP	B-protein
Coumadin	Coumadin	NN	I-NP	I-protein
.	.	.	O	O

Disposition	Disposition	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Physical	Physical	NNP	I-NP	O
Therapy	Therapy	NNP	I-NP	O
Service	Service	NNP	I-NP	O
while	while	IN	B-SBAR	O
an	an	DT	B-NP	O
inpatient	inpatient	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
inpatient	inpatient	JJ	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
allopurinol	allopurinol	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
amitriptyline	amitriptyline	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-NP	O
twice	twice	RB	I-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Aranesp	Aranesp	IN	B-NP	O
40	40	CD	I-NP	O
mcg	mcg	NN	I-NP	O
subcutaneous	subcutaneous	JJ	I-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
,	,	,	O	O
Benadryl	Benadryl	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
every	every	DT	B-NP	O
six	six	CD	I-NP	O
hours	hour	NNS	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
itching	itch	VBG	B-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-NP	O
twice	twice	RB	I-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
flecainide	flecainide	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
NovoLog	NovoLog	NNP	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
before	before	IN	B-PP	O
meals	meal	NNS	B-NP	O
and	and	CC	O	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
-	-	HYPH	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
125	125	CD	B-NP	O
give	give	VB	B-VP	O
zero	zero	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
125-150	125-150	CD	I-NP	O
give	give	VBP	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
151-200	151-200	CD	I-NP	O
give	give	VBP	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
201-250	201-250	CD	I-NP	O
give	give	VBP	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
251-300	251-300	CD	I-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
301-350	301-350	CD	I-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
351-400	351-400	CD	I-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
and	and	CC	O	O
call	call	VB	B-VP	O
physician	physician	NN	B-NP	O
if	if	IN	B-SBAR	O
fingerstick	fingerstick	NN	B-NP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
400	400	CD	B-NP	O
or	or	CC	O	O
less	less	JJR	B-NP	O
than	than	IN	B-PP	O
70	70	CD	B-NP	O
,	,	,	O	O
NovoLog	NovoLog	NNP	B-NP	O
40	40	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-ADJP	O
before	before	IN	B-PP	O
meals	meal	NNS	B-NP	O
-	-	HYPH	B-NP	O
please	please	NN	I-NP	O
hold	hold	NN	I-NP	O
if	if	IN	B-SBAR	O
n.p.o.	n.p.o.	NN	B-NP	O
,	,	,	O	O
levothyroxine	levothyroxine	NN	B-NP	O
75	75	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
milk	milk	NN	B-NP	O
of	of	IN	B-PP	O
magnesia	magnesia	NN	B-NP	O
30	30	CD	I-NP	O
mL	mL	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
constipation	constipation	NN	B-NP	O
,	,	,	O	O
metoprolol	metoprolol	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

-	-	HYPH	B-NP	O
hold	hold	NN	I-NP	O
if	if	IN	B-SBAR	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
90	90	CD	I-NP	O
or	or	CC	I-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
55-to	55-to	JJ	B-ADJP	O
be	be	VB	B-VP	O
discontinued	discontinue	VBN	I-VP	O
after	after	IN	B-PP	O
one	one	CD	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
then	then	RB	I-VP	O
be	be	VB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Nadolol	Nadolol	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	NN	I-NP	O
qday	qday	NN	I-NP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-NP	O
twice	twice	RB	I-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Avandia	Avandia	NNP	B-NP	O
4	4	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
at	at	IN	B-PP	O
noon	noon	RB	B-NP	O
daily	daily	JJ	I-NP	O
-	-	HYPH	I-NP	O
please	please	NN	I-NP	O
hold	hold	NN	I-NP	O
if	if	IN	B-SBAR	O
n.p.o.	n.p.o.	NN	B-NP	O
,	,	,	O	O
Sarna	Sarna	NNP	B-NP	O
topical	topical	JJ	B-ADJP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Zocor	Zocor	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
once	once	RB	I-ADVP	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
,	,	,	O	O
Tucks	Tuck	VBZ	B-VP	O
PR	PR	NN	B-NP	B-protein
daily	daily	RB	B-ADVP	O
,	,	,	O	O
spironolactone	spironolactone	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
calcitriol	calcitriol	NN	B-NP	O
0.25	0.25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

FOLLOW	FOLLOW	RB	B-ADVP	O
UP	UP	NN	B-NP	O
APPOINTMENTS	APPOINTMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Petramale	Petramale	NNP	I-NP	O
,	,	,	O	O
317-001-4753	317-001-4753	CD	B-NP	O
,	,	,	O	O
Hsey	Hsey	NNP	B-NP	O
Ochap	Ochap	NNP	I-NP	O
Debo	Debo	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
in	in	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Mucci	Mucci	NNP	I-NP	O
,	,	,	O	O
151-030-7040	151-030-7040	CD	B-NP	O
in	in	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Wailes	Wailes	NNP	I-NP	O
,	,	,	O	O
187-364-7139	187-364-7139	CD	B-NP	O
,	,	,	O	O
Hematology	Hematology	NNP	B-NP	O
at	at	IN	B-PP	O
Beplatte	Beplatte	NNP	B-NP	O
A	A	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
in	in	IN	B-PP	O
one	one	CD	B-NP	O
month	month	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Nephrologist	Nephrologist	NN	B-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
arranged	arrange	VBN	I-VP	O
DIET	DIET	NN	B-NP	O
:	:	:	O	O
Mechanical	Mechanical	JJ	B-NP	O
soft	soft	JJ	I-NP	O
honey	honey	NN	I-NP	O
consistency	consistency	NN	I-NP	O
.	.	.	O	O

Advance	Advance	NN	B-NP	O
as	as	IN	B-PP	O
tolerated	tolerate	VBN	B-VP	O
.	.	.	O	O

ADA	ADA	IN	B-PP	O
2000	2000	CD	B-NP	O
calories	calorie	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
2	2	CD	B-NP	O
grams	gram	NNS	I-NP	O
potassium	potassium	VBP	B-VP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
renal	renal	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

ACTIVITY	ACTIVITY	NN	B-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-VP	O
.	.	.	O	O

TO	TO	TO	B-PP	B-protein
DO	DO	NNP	B-NP	I-protein
:	:	:	O	I-protein
1	1	CD	B-NP	I-protein
.	.	.	O	O

Wound	Wound	JJ	B-NP	O
care	care	NN	I-NP	O
for	for	IN	B-PP	O
decubitus	decubitus	NN	B-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Follow	Follow	JJ	B-NP	O
appointments	appointment	NNS	I-NP	O
with	with	IN	B-PP	O
primary	primary	JJ	B-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
,	,	,	O	O
Hematology	Hematology	NNP	B-NP	O
,	,	,	O	O
Nephrology	Nephrology	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Vascular	Vascular	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
check	check	NN	B-NP	O
fingersticks	fingerstick	NNS	I-NP	O
before	before	IN	B-PP	O
meals	meal	NNS	B-NP	O
and	and	CC	O	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
follow	follow	VB	I-VP	O
INR	INR	NN	B-NP	B-protein
every	every	DT	B-NP	O
two	two	CD	I-NP	O
days	day	NNS	I-NP	O
with	with	IN	B-PP	O
goal	goal	NN	B-NP	O
INR	INR	NN	I-NP	O
of	of	IN	B-PP	O
2-3	2-3	NN	B-NP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
measure	measure	VB	I-VP	O
daily	daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
weight	weight	NN	B-NP	O
increases	increase	NNS	I-NP	O
by	by	IN	B-PP	O
three	three	CD	B-NP	O
pounds	pound	NNS	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
notify	notify	VBP	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Crisler	Crisler	NNP	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

T.i.d.	T.i.d.	LS	B-NP	O
wet-to-dry	wet-to-dry	JJ	I-NP	O
dressings	dressing	NNS	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
applied	apply	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
up	up	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
thigh	thigh	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
full	full	JJ	I-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
0-8683953	0-8683953	CD	B-NP	O
CSSten	CSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
GEEDING	GEEDING	NNP	B-NP	O
,	,	,	O	O
JERROD	JERROD	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
HUGUELEY	HUGUELEY	NNP	B-NP	O
,	,	,	O	O
ROSARIO	ROSARIO	NNP	B-NP	O
OMAR	OMAR	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
9262181	9262181	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
2/13/06	2/13/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
2/13/06	2/13/06	CD	B-NP	O

